A5042223616- Childhood Cancer Survivors' Quality of Life
- Chemotherapy-induced cardiotoxicity and mitigation
- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Cancer survivorship and care
- Acute Myeloid Leukemia Research
- Family Support in Illness
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- Adolescent and Pediatric Healthcare
- Hematopoietic Stem Cell Transplantation
- T-cell and B-cell Immunology
- Testicular diseases and treatments
- Ethics and Legal Issues in Pediatric Healthcare
- Cancer Treatment and Pharmacology
- Musculoskeletal Disorders and Rehabilitation
- Surgical site infection prevention
- Polymer Nanocomposite Synthesis and Irradiation
- PARP inhibition in cancer therapy
- Melanoma and MAPK Pathways
- Chromatin Remodeling and Cancer
University of Arizona
2014-2024
University of Arizona Cancer Center
2016-2019
Covance (United States)
2019
Pediatrics and Genetics
2013-2016
Banner - University Medical Center Tucson
2016
The University of Texas MD Anderson Cancer Center
2008-2013
Weatherford College
2008
NK cells have therapeutic potential for a wide variety of human malignancies. However, because expand poorly in vitro, limited life spans vivo, and represent small fraction peripheral white blood cells, obtaining sufficient cell numbers is the major obstacle NK-cell immunotherapy. Genetically-engineered artificial antigen-presenting (aAPCs) expressing membrane-bound IL-15 (mbIL15) been used to propagate clinical-grade trials adoptive immunotherapy, but ex vivo proliferation has by telomere...
For survivors of childhood cancer treated with doxorubicin, dexrazoxane is cardioprotective for at least 5 years. However, longer-term data are lacking.
Background The objective of this study was to examine long‐term outcomes among children newly diagnosed with cancer who were treated in dexrazoxane‐containing clinical trials. Methods P9404 (acute lymphoblastic leukemia/lymphoma [ALL]), P9425 and P9426 (Hodgkin lymphoma), P9754 (osteosarcoma), Dana‐Farber Cancer Institute 95‐01 (ALL) enrolled 1308 patients between 1996 2001: 1066 randomized (1:1) doxorubicin or without dexrazoxane, 242 (from P9754) nonrandomly assigned receive dexrazoxane....
Dexrazoxane protects from lower-cumulative-dose doxorubicin cardiotoxicity, but the effect of dexrazoxane in children with sarcoma treated higher-cumulative-dose is unknown.We evaluated osteosarcoma (OS) on two Children's Oncology Group trials higher dose (375-600 mg/m2) preceded by (10:1 dexrazoxane:doxorubicin dosing). They were after minimum expected treatment time (METT), defined as 28 weeks. Cardiotoxicity was identified echocardiography and serum N-terminal pro-brain natriuretic...
The current standard of care for initial staging pediatric Ewing sarcoma (EWS) patients is to obtain a bilateral bone marrow aspiration and biopsy (BMAB). incidence (BM) disease in deemed non-metastatic by conventional metabolic imaging the concordance BM positivity with other clinical characteristics are not well established.This study multi-institutional retrospective review newly diagnosed EWS less than 40 years age that included BMAB.A total 116 were eligible 85 considered 31 metastatic...
Childhood cancer survivors are at risk for cardiovascular disease. We assessed the burden of potentially modifiable cardiometabolic factors (CRF) among compared with population-matched controls.Survivors previously enrolled on Pediatric Oncology Group protocols 9404, 9425, 9426, 9754, and Dana-Farber Cancer Institute 95-01 from 1996 to 2001 acute lymphoblastic leukemia/lymphoma, Hodgkin lymphoma, or osteosarcoma were prospectively prevalence CRFs an age, sex, race/ethnicity-matched 2013...
There are limited data on the incidence of delirium in children with cancer. We performed a retrospective chart review all pediatric oncology admissions over 1 year period to determine this population. identified seven patients (10% incidence). Delirium is associated significant morbidity and mortality, likely under-recognized Improved diagnosis treatment may improve outcomes
Purpose: The aim of this study was to describe diet and physical activity (PA) behaviors health beliefs among cancer survivors identify potential differences between adolescent young adult (AYA) adult/older survivors. Methods: Cancer (n = 1864) participating in the Health Information National Trends Survey (HINTS) provided responses regarding PA selected related general (self-efficacy, attitudinal belief, normative risk intention, self-regulation). belief associations with were assessed...
Abstract Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid (AML). Treatment pediatric APL based on the combination all‐ trans ‐retinoic acid (ATRA), an anthracycline and cytosine arabinoside. Arsenic trioxide (ATO) has been studied in adults with newly diagnosed or relapsed excellent response rates both when used as single agent ATRA plus chemotherapy. There little data therapy ATO APL. We present case adolescent male who was treated using without conventional...
Busulfan, fludarabine, and melphalan as hematopoietic cell transplant conditioning, was used in 6 patients aged 1 to 19 years with very high-risk myeloid malignancies. This dose regimen had an acceptable toxicity profile resulting complete donor engraftment even following transplantation of small 2/6 antigen disparate umbilical cord blood grafts. It provided excellent disease control all features terms cytogenetics, therapy-related leukemia, and/or significant measurable before transplant....
Summary Over 50% of patients with systemic LCH are not cured front‐line therapies, and data to guide salvage options limited. We describe 58 who were treated clofarabine. Clofarabine monotherapy was active against in this cohort, including heavily pretreated a objective response rate 92.6%, higher children (93.8%) than adults (83.3%). BRAF V600E+ variant allele frequency peripheral blood is correlated clinical responses. Prospective multicentre trials warranted determine optimal dosing,...
9503 Background: Anthracyclines are highly efficacious in OS but associated with risk of cardiotoxicity. We conducted two studies using dexrazoxane as a cardioprotectant: i) AOST0121, phase II study for metastatic and ii) P9754, series pilot including doxorubicin dose intensification patients localized OS. Methods: Patients on AOST0121 received methotrexate, (375 mg/m 2 ), cisplatin, ifosfamide etoposide (MAPIE). Those HER2-positive tumors also trastuzumab (4 mg/kg loading dose, weekly). On...
5039 Background: Standard-of-care (SOC) chemotherapy may contribute to immunosuppression by elevating intratumoral levels of adenosine, activating the A 2a and 2b receptors on immune cells. Extracellular adenosine is primarily produced enzyme CD73; in prostate cancer, additional also highly expressed protein, prostatic acid phosphatase (PAP). Etrumadenant (etruma) an orally bioavailable, small-molecule, selective dual receptor antagonist has been well tolerated dose escalation studies as...
Relapse of acute lymphoblastic leukemia (ALL) in the breast is uncommon and often precedes systemic relapse, resulting poor survival. We report development involvement ALL a 20-year-old woman 32 months after related allogeneic peripheral blood hematopoietic cell transplantation (PBHCT) first remission. This extramedullary relapse occurred continuous presence complete donor chimerism. After re-induction chemotherapy second PBHCT using cells that had been cryopreserved at transplant, our...
Abstract Introduction Surgical site infection (SSI) is the most common and costly complication of surgery. International guidelines recommend topical alcoholic chlorhexidine (CHX) before However, upper limb surgeons continue to use other antiseptics, citing a lack applicable evidence, concerns related open wounds tourniquets. This study aimed evaluate safety effectiveness different antiseptics Methods international multicentre prospective cohort recruited consecutive adults children who...
ARST1321, a trial of patients with advanced soft tissue sarcoma, was the first National Clinical Trials Network study codeveloped by pediatric and adult consortia two treatment cohorts. We report on findings survey to identify barriers enrolling adolescent young (15–39 years) onto nonchemotherapy arm. The response rate 31% 70% completion rate. Common identified reasons for low accrual in order decreasing frequency included insufficient funding, lack awareness or interest, competing trials,...